Merck & Company, Inc. News Headlines

MRK 
$60.58
*  
0.09
0.15%
Get MRK Alerts
*Delayed - data as of Sep. 22, 2014  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Merck Gets FDA Approval For New Formulation Of Isentress As It Continues To Focus On Anti-Infectives
1/10/2014 2:32:05 PM - Trefis

Forest Labs Soars on Aptalis Deal - Analyst Blog
1/9/2014 2:10:01 PM - Zacks.com

AZN and Horizon Discovery Ink Deal - Analyst Blog
1/8/2014 6:02:01 PM - Zacks.com

Dogs Barking In The Dow, Value Or Warning Signals?
1/8/2014 3:36:00 PM - Seeking Alpha

3 Must-Sell Dow Stocks For 2014
1/8/2014 9:58:00 AM - Seeking Alpha

Pick GlaxoSmithKline For A Sustainable 4.6% Yield
1/7/2014 6:50:00 PM - Seeking Alpha

Looking At China's Importance For Pfizer As The Diflucan's Imports Hit A Bump
1/6/2014 2:31:08 PM - Trefis

Positive Data on Amgen's Romosozumab - Analyst Blog
1/3/2014 5:50:01 PM - Zacks.com

Tetraphase Pharmaceuticals: A Small Cap With Big Potential
1/3/2014 3:10:00 PM - Seeking Alpha

Cramer's Mad Money - 2014 Dow Predictions (1/2/14)
1/3/2014 5:54:00 AM - Seeking Alpha

Gilead Seeks To Expand Its Blockbuster Hepatitis Platforms In 2014
1/3/2014 2:27:00 AM - Seeking Alpha

Merck & Co., Inc. (MRK): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report
12/31/2013 8:00:01 AM - Zacks.com

Actavis' Women Health Biz Update - Analyst Blog
12/30/2013 3:51:01 PM - Zacks.com

Johnson & Johnson: The Year 2013 In Review
12/30/2013 2:11:03 PM - Trefis

Healthcare Stocks Split Between Winners, Losers - Merck, Partner Sending Allergy Drug Before FDA Advisory Panel
12/27/2013 4:45:01 PM - MT Newswires

Sector Update: Healthcare
12/27/2013 4:43:18 PM - MT Newswires

Why Tudor sold its position in Forest Laboratories?
12/25/2013 8:00:00 AM - Market Realist

Dividends: Big Dogs, Small Dogs And Spy Dogs
12/25/2013 4:11:00 AM - Seeking Alpha

After Hours Most Active for Dec 24, 2013 : S, QQQ, MS, MRK, GE, M, TEVA
12/24/2013 5:33:51 PM - NASDAQ.com News

Why did Tudor exit Merck & Co?
12/24/2013 4:00:00 PM - Market Realist

Will Merck Be Able To Sustain Its Dividends?
12/24/2013 3:55:00 PM - Seeking Alpha

TESARO Plunges on Study Results - Analyst Blog
12/24/2013 12:17:42 PM - Zacks.com

Why did Tudor buy Intercontinental Exchange?
12/24/2013 12:00:00 PM - Market Realist

Dow Dogs Drink To A Dominant 2013. Will They Toast A Triumphant 2014, Too?
12/24/2013 10:38:00 AM - Seeking Alpha

Cervical Cancer Should Not Be Ignored By Biotech Investors
12/24/2013 9:59:00 AM - Seeking Alpha